What's happening
This bill requires opioid treatment facilities in New York to have at least one qualified practitioner able to prescribe buprenorphine.
Why it matters
Expands access to medication-assisted treatment. By requiring at least one qualified practitioner per facility to be able to prescribe buprenorphine, the bill aims to reduce barriers for patients seeking evidence-based treatment for opioid use disorder, which can improve recovery rates and save lives.
Addresses provider training gaps. The mandate for practitioners to obtain necessary waivers or training responds to a key bottleneck in opioid treatment—many facilities currently lack staff authorized to prescribe buprenorphine, limiting patient options.
Reduces risk of opioid overdose deaths. Increasing the availability of buprenorphine, a medication proven to reduce cravings and prevent overdoses, can help combat the ongoing opioid epidemic in New York by making this lifesaving treatment more widely available.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Require Buprenorphine in Treatment
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Print number 705b
- Amend and recommit to ways and means
- Referred to ways and means
- Reported referred to ways and means
- Print number 705a
- Amend and recommit to alcoholism and drug abuse
- Referred to alcoholism and drug abuse
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Buprenorphine Access
In Assembly Committee · Ways And Means · Sponsor Pete Harckham
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
705--B
2021-2022 Regular Sessions
IN ASSEMBLY (Prefiled)
January 6, 2021
Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Alcoholism and Drug Abuse -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- reported and referred to the Committee on Ways and Means -recommitted to the Committee on Ways and Means in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the mental hygiene law, in relation to the availability of buprenorphine in opioid treatment programs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The mental hygiene law is amended by adding a new section 32.12 to read as follows: § 32.12 Availability of buprenorphine.
Every facility licensed or authorized to provide services for substance use disorders related to opioids that employs a qualified practitioner, as determined by federal law, shall ensure at least one practitioner in the facility has received an appropriate waiver and/or has completed required training to administer or prescribe buprenorphine to individuals in their care with a substance use disorder where such drug is determined appropriate for their treatment.
§ 2. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00547-06-2
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.